Digestive Health Newsletter

Know Your Rights: IBD and Employment

Jennifer C. Jaff, Esq.

Volume 13, 
January 01, 2009

by Jennifer C. Jaff, Esq.

Jennifer C. Jaff, Esq. Jennifer C. Jaff graduated with honors from Georgetown University Law Center in 1984. She was an Assistant Attorney General for the State of Connecticut for five years, where she specialized in health law and Medicaid fraud, bringing the first civil RICO cases on behalf of a State in US History. Ms Jaff spent a year as counsel to government relations departments at national reproductive health organizations, and in private practice, focused on large class actions involving employee benefits. She founded Advocacy for Patients with Chronic Illness, Inc, in 2005 and has served as its Executive Director since that time. She is the author of Know Your Rights: A Handbook for Patients with Chronic Illness, and is the Chronic Illness Advocate for RevolutionHealth.com.

Table of Contents

Introduction

If you are one of the approximately 1.4 million Americans with inflammatory bowel disease (IBD), your rights have begun to receive notice and protection, but there is much more to be done. Federal laws like the Americans with Disabilities Act (ADA) have, until now, focused primarily on people in wheelchairs, the blind, the deaf, and not those of us with largely invisible chronic illnesses like Crohn's disease and ulcerative colitis. And, until recently, the law did not incorporate the notion of "chronicity" – the one–word label I use to distinguish chronic illness from either illness from which you recover or terminal illness – which left those of us with chronic illnesses trying to fit our disease into a model that was not designed with us in mind, like trying to put a round peg into a square hole. This newsletter will focus on some of the employment–related questions that you may have as you try to navigate life with IBD. It will also explain how disability–related legislation can work in your favor.

Back to Top

Americans with Disabilities Act

Is IBD considered a disability under the ADA?

By far, the most common question I am asked is whether Crohn's disease or ulcerative colitis are disabilities under the ADA. The ADA defines "disability" as a condition that must substantially limit a major life activity1. There are two parts to that definition: "major life activity" and "substantially limit." We will discuss each in turn.

In the past, the ADA has defined a "major life activity" as including but not limited to "caring for oneself, performing manual tasks, seeing, hearing, eating, sleeping, walking, standing, lifting, bending, speaking, breathing, learning, reading, concentrating, thinking, communicating, and working." Since major bodily functions, like those related to the digestive and bowel systems, were not included in the list, the burden was on us to make the case that IBD fit the definition.

However, this past fall, Congress passed the ADA Amendments of 2008, which took effect on January 1, 2009. The Amendments state that "disability" includes major bodily functions, including but not limited to the immune, digestive, and bowel systems. So, starting this year, there is no question that IBD is considered a disability under the ADA.

In the past, employers also were able to argue that chronic illnesses that come and go do not constitute "substantial limitations" on major life activities, because they do not limit activities on days when they are in remission. The 2008 Amendments also address this issue. They say that chronic illnesses that would be disabling when active are considered "disabilities" all the time, including when they are in remission. This appears to be the first recognition of "chronicity" in US law and, as such, it represents a real advance for IBD patients.

Thus, although we always had strong arguments that IBD constitutes a "disability," and we won many cases under the old law, there is now no doubt about it: IBD is a disability under the ADA.

Does the fact that I have a disability automatically mean I am entitled to protection under the ADA?

No. To be entitled to protection under the ADA, you have to be a "qualified individual" with a disability. Thus, you can be disabled but not "qualified." To be "qualified" under the ADA, you have to be able to perform the "essential functions" of your job with or without accommodation. The "essential functions" of your job are the fundamental duties of the employment position you hold (ie, typically those listed in your written job description).

More specifically, if attendance is an "essential function" of your job and your illness prevents you from getting to work every day, you may not be protected by the ADA, even with the 2008 Amendments. For example, if you work in a call center or as a salesperson in a showroom, then your job requires your presence in the workplace. Even if you are disabled, you may not be entitled to the protections of the ADA because, even with accommodation, you can't perform the "essential function" of being present in the workplace every day. On the other hand, if you have the sort of job that can be done from home, and allowing you to work from home does not constitute an "undue burden" on your employer, then you might be considered to be a "qualified" individual.

Does the ADA protect me even if my IBD is controlled by medication?

Prior to the ADA Amendments of 2008, the answer to this question was no. However, the new Amendments also address this issue. As of January 1, 2009, you are considered disabled even if your IBD is controlled by medication, surgery, or other ameliorating measures. For example, an ostomy cannot be construed as a solution to your disease unless it means you will no longer have flares or other symptoms. Likewise, a so–called ameliorating measure that leaves you with a new set of symptoms will not be found to eliminate your disability.

Back to Top

Employment-related rights

What are my rights when I apply for a job?

According to Title I of the ADA (which is the section that relates to employment), you cannot be discriminated against during the recruitment or hiring process. For example, Title I restricts the questions that a prospective employer can ask about your disability before making a job offer. Note, however, that Title I applies only to employers with 15 or more employees in 20 nonconsecutive workweeks of the current or preceding calendar year. Your state may have a law that applies similar protections to smaller employers.

I often am asked whether a job applicant should disclose that he or she has IBD. In my view, there are only two reasons to disclose your IBD: if you are requesting accommodations under the ADA, or if you are requesting leave under the Family & Medical Leave Act2. Both of these will be discussed in more detail below.

Employers are allowed to ask some health–related questions in a job interview. For example, they can ask how you handle stress, whether you work well under pressure, and whether you have a physical condition that would interfere with your ability to do your job; however, they cannot ask whether you have a chronic illness, whether you have a disability that would prevent you from performing the essential functions of the job even with accommodation, or whether you would need reasonable accommodations if you were hired.

Job offers also can be contingent on passing a medical exam. This is permitted only if all candidates for a job are given the same test. The physical exam cannot exclude you because you have IBD; it can exclude you only if your IBD would make it impossible for you to perform the essential functions of your job with or without accommodation. It is not the label that counts; it is your ability to function (ie, what you can and cannot do).

What are my rights at work?

Title I of the ADA protects qualified individuals with disabilities from discrimination with respect to recruitment, hiring, promotion, training, pay, social activities, and other privileges of employment. It requires employers to provide equal opportunities to qualified individuals with disabilities, and to protect you against discrimination or harassment due to your disability.

In addition, if you have physical limitations but are otherwise qualified for employment, the ADA requires your employer to make "reasonable accommodations" unless doing so results in an "undue hardship" for the employer.

What are "reasonable accommodations"?

A reasonable accommodation is a modification or adjustment to a job or the work environment that will enable a qualified individual with a disability to perform the essential functions of the job. Accommodations may be as simple as relocating an employee's desk so that it is near a bathroom, or as complex as job restructuring, modification of work schedules, acquiring or modifying equipment, or reassigning an employee to a vacant position that is available and for which the employee is qualified.

This does not mean that everybody who asks for a modified work schedule gets one. Accommodations are considered to be reasonable if they do not impose an undue hardship on the employer. Undue hardship is "action requiring significant difficulty or expense." Whether a particular accommodation constitutes an undue hardship depends on the context. For example, if you are one of ten secretaries answering phones, and you need frequent breaks to use a restroom, that might be reasonable because there are nine other secretaries and it would not be an undue hardship to ask them to cover for you. On the other hand, if you are the only receptionist in a smaller office, having someone cover for you might be considered an undue hardship.

Typically, reasonable accommodations are negotiated. Your employer doesn't have to give you the exact accommodation you request; instead, he or she must engage in an "interactive process" to try to arrive at an accommodation that will meet your medical needs and also satisfy his or her business needs.

How do I request a reasonable accommodation?

An employer is required to make a reasonable accommodation only when there is a known disability. Usually, the employee requests an accommodation. In most cases, if the employee does not ask for an accommodation, the employer is not required to provide one.

To request reasonable accommodation, you must do so in writing. Your employer may have forms for you to use, or you may be able to submit a note simply stating the nature of your disability and the accommodation you are requesting. You also will need to submit medical information. The amount of medical information you need will depend, to some extent, on the employer. I have seen employers accept a brief note, and I have seen employers send an employee to an outside or company physician for examination. Any medical inquiry must focus on the precise need for, and nature of, the accommodation.

Keep in mind that all accommodations are the result of an "interactive process" between employer and employee. The law does not require an employer to give you the accommodation you want. It is a process of negotiation to accommodate you in a way that meets your medical needs with the least burden on the employer. There are no limits on what you and your employer can consider. Creativity can be a plus when an employer says no to one proposal, but is open to considering others. You should participate actively in this sort of negotiation, and be prepared for genuine give and take. This usually is the best opportunity you will have to reach a good resolution, while maintaining a good relationship with your employer.

What can I do if I think my rights have been violated?

If you think you have been discriminated against, you should contact your local office of the Equal Employment Opportunity Commission (EEOC). You can find your local office here: www.eeoc.gov/offices.html. Many state and local governments also have fair employment practices laws and state agencies that administer those laws. You can file a complaint with one of those agencies, as well. When you file a disability discrimination complaint with either the state agency or the EEOC, you "dual file" with both. If you file with the state agency, the state agency investigates the complaint; if you file with the EEOC, the EEOC holds onto the complaint. Either way, your complaint is investigated and evaluated under both state and federal law. And either way, there is no cost to filing a complaint.

You have 180 days from the last act of discrimination to file a complaint. Typically, you will be asked for any documentation of your claim, and then you will be asked if you are interested in mediating your dispute. Mediation is not an opportunity to argue the merits of your case; its purpose is to see if you and your employer (or former employer) can reach a negotiated settlement of your complaint.

Although you certainly can file a complaint without the assistance of an attorney, experienced attorneys who have engaged in many negotiations will be very helpful at the mediation stage, as well as beyond it. Some lawyers take employment discrimination cases on a contingent basis, which means they get paid only if they win, and they get roughly one–third of what you win. Keep in mind that, if an attorney takes your case on a contingent basis and you lose, you may still have to pay the costs of litigation.

Once you file a complaint and either try and fail to reach a mediated settlement or skip mediation entirely, either the state agency or the EEOC will investigate the case. Once the investigation is completed, the state agency or the EEOC will decide whether it believes discrimination occurred. At that point, you or your employer (or former employer) can request an administrative hearing, which is less formal than court. If you choose that avenue, the evidence before the hearing officer will be the evidence obtained during the investigation.

Instead of requesting an administrative hearing, ninety days after you file a complaint, you have the right to direct the investigation to end, and to take the case directly to court. This is called asking for a "right to sue" letter. Many experienced employment attorneys do this as a matter of course because investigations take a long time and attorneys may feel that they have more control over the proceedings once the case is out of the agency's hands. However, if you do not have an attorney, the court process can be technical and daunting. In that case, you may want to let the investigative process play itself out.

Do the 2008 Amendments mean I can get disability benefits if I was turned down before?

No. The ADA prohibits discrimination on the basis of disability and requires employers (and others) to provide reasonable accommodations, but it has no impact on the definition of "disability" used by the Social Security Administration and, therefore, no impact on your ability to obtain Social Security disability benefits.

Back to Top

Family and Medical Leave Act

What is the Family and Medical Leave Act?

The Family and Medical Leave Act (FMLA) provides eligible employees with a total of up to 12 workweeks of leave during a 12–month period for one or more of the following reasons:

 

Whether or not you are paid for your leave is up to your employer. Some employers cover portions of leave, for example you may receive pay during the first four weeks of maternity leave, but no pay for the remainder of the leave. Others may compensate you during your leave if you use accrued vacation days. If you were receiving health insurance benefits prior to your leave, you are entitled to continue receiving those benefits during your leave. Finally, following your leave, you are entitled to return to your original job or a similar job with equivalent pay and benefits.

The FMLA applies to all public agencies (state, local, and federal), including schools, and to private–sector businesses that employ 50 or more employees in 20 or more nonconsecutive workweeks in the current or preceding calendar year.

The FMLA applies only to an employee who has been working for the same (or a successor) employer for at least 12 months, for at least 1,250 hours during the previous 12 months, at a location where at least 50 employees are employed by the employer within 75 miles. The 12 months of employment need not be consecutive, and the 1,250 hours cannot include paid or unpaid leave; it includes only hours actually worked. Whether the employee has satisfied the 12 month/1,250 hour requirement is determined as of the date the leave would commence. The 50 employee/75 mile requirement, however, must be met as of the date the employee gives notice of the need for leave.

How do I request FMLA leave?

There are no magic words necessary for an employee to request leave. Generally, it is the employee's responsibility to give notice of the need for leave. Notice may be given either in person or by telephone, telegraph, fax machine or by other electronic means. Someone other than an employee may give the notice. Notice includes advising the employer of the anticipated timing and duration of leave. Simply saying, "I have lupus" is insufficient. Note that many courts have said that an employer's knowledge of an employee's medical condition and that the employee was seeing a doctor does not mean that the employer had notice of the employee's need for leave.

Filing an FMLA complaint is similar to filing a discrimination–related complaint, except that you do so with the Wage and Hour Division of the US Department of Labor (http://www.dol.gov/esa/whd/).

What if I need a day here and there, but not twelve consecutive weeks?

An employee can take the leave to receive "continuing treatment by a healthcare provider," including physical therapy or intravenous therapy such as Remicade or IVIg or chemotherapy, which takes a few hours. You do not have to use all of your leave consecutively; you can use it intermittently.

Back to Top

Conclusion

The FMLA is your best protection against being fired if your issue is absenteeism. However, the ADA will protect you if you require other types of accommodations. The ADA Amendments of 2008, which went into effect on January 1, 2009, represent a huge advancement for patients with IBD, and should make it far easier for IBD patients to obtain reasonable accommodations. Note that individual states have added certain restrictions on both the ADA and the FMLA, which may give you additional rights depending on where you live.




  1. 42 U.S.C. § 12101 et seq.
  2. 29 U.S.C. § 2601 et seq.


Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with AZASAN. See WARNINGS.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms. Patients are at increased risk of developing lymphoma and other malignancies, particularly of the skin. Exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and a high SPF sunscreen. Patients should have complete blood count (CBC), including platelet counts periodically during treatment. TPMT testing should be conducted to identify with absent or reduced TPMT activity. The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with AZASAN. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: salix@medcomsol.com

Please see complete Prescribing Information for AZASAN, including BOXED WARNING.pdf

Indication for METOZOLV ODT

METOZOLV® ODT is indicated for short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease that fails to respond to conventional therapy (refractory GERD) and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (gastric stasis) in adults.

Important Safety Information about METOZOLV ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) orally disintegrating tablet therapy should not exceed 12 weeks in duration and is recommended for adults only (the safety and effectiveness in pediatric patients have not been established).

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age, and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Patients may experience withdrawal symptoms after stopping METOZOLV ODT that could include dizziness, nervousness, and/or headaches.

METOZOLV ODT interacts with anticholinergics, narcotic analgesics, monoamine oxidase inhibitors, insulin, antidepressants, antipsychotics, and neuroleptics. METOZOLV ODT may alter drug absorption.

Elderly patients may be more sensitive to adverse reactions such as sedation and drug-induced movement disorders. In patients with impaired renal function, initial dosing may need to be reduced and titrated.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) for METOZOLV ODT were headache, nausea, fatigue, somnolence, and vomiting.

Please see complete Prescribing Information for METOZOLV ODT, including BOXED WARNING. pdf

Indication for OSMOPREP

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are contraindicated in patients with a biopsy-proven acute phosphate nephropathy, gastrointestinal (GI) obstruction, gastric bypass or stapling surgery, bowel perforation, toxic colitis, toxic megacolon, and known allergy or hypersensitivity to sodium phosphate salts or any component of OSMOPREP.

Renal impairment may occur with OSMOPREP. Assess renal function before treatment and during therapy. Use OSMOPREP with caution in patients with impaired renal function (creatinine clearance less than 30mL/minute), patients with a history of acute phosphate nephropathy, known or suspected electrolyte disturbances (such as dehydration), or people taking concomitant medications that may affect electrolyte levels (such as diuretics). Patients with electrolyte abnormalities (such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia) should have their electrolytes corrected before treatment with OSMOPREP Tablets.

Seizures due to electrolyte abnormalities can occur. OSMOPREP should be used with caution in patients with a history of seizures or at higher risk of seizure [e.g. patients using concomitant medications that lower the seizure threshold (such as tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia].

Use caution in patients with higher risk of arrhythmias (e.g., patients with a history of cardiomyopathy, prolonged QT, uncontrolled arrhythmias, or recent myocardial infarction).

Advise patients to hydrate adequately before, during, and after the use of OSMOPREP.

Use OSMOPREP with caution in patients with history of Inflammatory Bowel Disease. In patients with suspected GI obstruction or perforation, rule out the diagnosis before administration of OSMOPREP.

Animal reproduction studies have not been performed. OSMOPREP should only be given to a pregnant woman if clearly needed.

In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, abdominal pain, nausea, and vomiting.

Please see complete Prescribing Information for OSMOPREP, including BOXED WARNING.pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.


Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter